Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic, Inc. (NASDAQ: HOLX) is set to release its financial results for Q2 2023 on May 1 after market close. A conference call will follow at 4:30 p.m. ET, where management will provide insights into the results. Interested participants can join the call by dialing the provided numbers or by click here to join. A replay will be available on Hologic's investor website.
Hologic, Inc. (NASDAQ: HOLX) will present at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:10 a.m. Eastern Time in Boston, MA. The conference runs from March 6-8 and includes various presentations and panel discussions on the health care industry. Hologic's presentation will be available via a live webcast on the company's investor website for 30 days post-event. Hologic is dedicated to enhancing women’s health through early detection and treatment innovations.
Hologic, Inc. (NASDAQ: HOLX) announced that the U.S. Court of Appeals for the Federal Circuit upheld a 2021 ruling that invalidated a Minerva patent related to its NovaSure system. The court determined Minerva's patent was invalid due to a delay in filing after showcasing a prototype. This decision aligns with the previous district court judgment, which favored Hologic just before trial. In a related case, Minerva was ordered to pay Hologic over $7.4 million for infringing a Hologic patent. NovaSure, approved by the FDA in 2001, is a minimally invasive procedure for treating abnormal uterine bleeding, with a 77.7% efficacy rate and 92.8% patient satisfaction.
Hologic Inc. announced the approval of its NovaSure® V5 global endometrial ablation device in Canada and Europe. This advanced version features enhanced technology aimed at treating diverse cervical and uterine anatomies, enhancing patient outcomes. With over 3 million women treated globally, the NovaSure V5 offers a 97% patient satisfaction rate and an 87% hysterectomy avoidance rate at ten years post-procedure. Key improvements include an updated cervical seal and enhanced accuracy markings. The company emphasizes ongoing commitment to innovation in women's health.
Hologic, Inc. reported Q1 FY2023 revenue of $1,074 million, surpassing guidance of $940 to $990 million, despite a 27% year-over-year decline primarily due to lower COVID-19 assay sales and semiconductor supply chain issues. GAAP diluted EPS stood at $0.75, down 61.5% from the prior year, with non-GAAP EPS of $1.07, a 50.7% decline. The company experienced a 15.8% revenue growth in Diagnostics, excluding COVID-19, and Surgical revenue grew by 14.7%. Hologic raised its fiscal 2023 revenue guidance to $3.85 billion - $4 billion and EPS guidance to $2.69 - $2.99, indicating confidence in growth despite challenges.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
